ODI Pharma

Third quarter (2025-01-01 - 2025-03-31)

• The Group's net sales amounted to SEK 2,934,337 (13,856,539).
• The Group's profit after financial items amounted to SEK -340,612 (1,389,713).
• Result per share amounted to SEK -0.02 (0.09).*

Nine months (2024-07-01 - 2025-03-31)

• The Group's net sales amounted to SEK 3,064,896 (14,777,194).
• The Group's profit after financial items amounted to SEK -4,153,493 (955,796).
• Result per share amounted to SEK -0.26 (0.06).*
• The solidity as of 2025-03-31 was 11% (23%).**

* The Company's result per share: The result for the period divided by the number of shares at the end of the period. The total number of shares as of 31st of March 2025, amounted to 15,915,034 (15,220,000) shares. The result per share based on the average number of shares of 15,915,034 (15,220,000) amounts to SEK -0.26 (0.06) for the nine months 2024-07-01 to 2025-03-31.  

** Solidity: Equity divided by total capital.

Highlights during the second quarter

• ODI Pharma announced the termination of its agreement with liquidity provider Pareto Securities AB, effective March 14, 2025. The agreement was originally established to increase trading liquidity and reduce share price volatility.

Highlights after the end of the period

• No significant events occurred after the end of the period.

For more information on ODI Pharma, please contact:

Volker Wiederrich, Chairman, ODI Pharma AB

E-mail: info@odipharma.com  

ODI Pharma AB

ODI Pharma, based on its European network, subsidiaries and affiliates, is a producer and representative of finished pharmaceutical cannabis products with a focus on distribution to the medical cannabis market in Europe through its subsidiary ODI Pharma Polska Sp. z o.o. ODI Pharma intends to provide a high-quality product at a competitive price compared to competitors in Poland, thereby becoming the number one provider of medical cannabis in Poland. ODI Pharma also strives to be on the forefront of understanding the medical applications of the product as well as introducing new, innovative products to the European patients in need. The Company will continue to team up with the most knowledgeable and best renown partners in the industry to achieve its goals.